Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $42 to $44.
May 02, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Corcept Therapeutics and raises the price target from $42 to $44.
The upgrade in the price target by Truist Securities reflects a positive outlook on Corcept Therapeutics, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100